Literature DB >> 15717660

Novel medical approaches for the treatment of Cushing's disease.

A P Heaney1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15717660     DOI： 10.1007/BF03347485

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  27 in total

1.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.

Authors:  I Issemann; S Green
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

Review 2.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

Review 3.  The biologic basis for the use of retinoids in cancer prevention and treatment.

Authors:  J M Kurie
Journal:  Curr Opin Oncol       Date:  1999-11       Impact factor: 3.645

4.  Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

Authors:  P Sarraf; E Mueller; D Jones; F J King; D J DeAngelo; J B Partridge; S A Holden; L B Chen; S Singer; C Fletcher; B M Spiegelman
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

5.  Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.

Authors:  R Pivonello; A Faggiano; F Di Salle; M Filippella; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

6.  Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome.

Authors:  A Tabarin; A Navarranne; J Guérin; J B Corcuff; M Parneix; P Roger
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

7.  Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.

Authors:  C Höybye; E Grenbäck; T Rähn; M Degerblad; M Thorén; A L Hulting
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

8.  Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

Authors:  X Bertagna; C Bertagna; M H Laudat; J M Husson; F Girard; J P Luton
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

9.  Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis.

Authors:  W M Drake; L A Perry; C J Hinds; D G Lowe; R H Reznek; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.

Authors:  L K Nieman; G P Chrousos; C Kellner; I M Spitz; B C Nisula; G B Cutler; G R Merriam; C W Bardin; D L Loriaux
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958
View more
  1 in total

1.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.